# A Case of Erythrodermic Psoriasis Successfully Treated With Ixekizumab Combined With Low-Dose Methotrexate to Ensure Sustained Clearance: A Case Report

## TL;DR

A severe case of psoriasis was successfully treated with a combination of ixekizumab and low-dose methotrexate, achieving sustained skin clearance.

## Contribution

The paper presents a novel treatment approach combining ixekizumab and low-dose methotrexate for refractory erythrodermic psoriasis.

## Key findings

- Ixekizumab combined with low-dose methotrexate effectively treated erythrodermic psoriasis.
- The combination therapy provided sustained skin clearance without significant safety concerns.
- This approach may be beneficial for patients unresponsive to conventional treatments.

## Abstract

Erythrodermic psoriasis (EP) is a severe type of psoriasis that requires immediate and effective treatment to prevent serious complications. Although recommended as first-line treatment for EP, conventional systemic disease–modifying antirheumatic drugs (csDMARDs) such as methotrexate and/or cyclosporine can sometimes be ineffective or undesirable, hence the use of biologics. However, in cases of refractory disease, biologics may be combined with methotrexate to boost efficacy and optimize outcomes without compromising safety and tolerability.